NORVIR CAPSULE
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
29-05-2019
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
RITONAVIR
Inapatikana kutoka:
ABBVIE CORPORATION
ATC kanuni:
J05AE03
INN (Jina la Kimataifa):
RITONAVIR
Kipimo:
100MG
Dawa fomu:
CAPSULE
Tungo:
RITONAVIR 100MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
2X84
Dawa ya aina:
Prescription
Eneo la matibabu:
HIV PROTEASE INHIBITORS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0128780001; AHFS:
Idhini hali ya:
CANCELLED POST MARKET
Idhini ya tarehe:
2012-11-08
Tabia za bidhaa
_ _
_NORVIR Product Monograph _
_Page 1 of 64 _
PRODUCT MONOGRAPH
PR
NORVIR
®
Ritonavir
film-coated tablets (100 mg)
Human Immunodeficiency Virus (HIV) Protease Inhibitor
AbbVie Corporation
Date of Revision:
8401 Trans-Canada Highway
May 29, 2019
St-Laurent, Qc H4S 1Z1
Submission Control No: 226180
_ _
_NORVIR Product Monograph _
_Page 2 of 64 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................23
DOSAGE AND ADMINISTRATION
..............................................................................42
OVERDOSAGE
................................................................................................................43
ACTION AND CLINICAL PHARMACOLOGY
............................................................44
STORAGE AND STABILITY
..........................................................................................48
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................48
PART II: SCIENTIFIC INFORMATION
................................................................................49
PHARMACEUTICAL INFORMATION
..........................................................................49
CLINICAL TRIALS
..........................................................................................................50
MICROBIOLOGY
...............
Soma hati kamili
